ExpreS2ion to present in upcoming investor and scientific events
Hørsholm, Denmark, 10 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including a webcast about the 2024 Rights Issue and the 2024 European Society for Animal Cell Technology (ESACT) meeting.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website and via the links below.
14 June 2024 | 2024 Rights Issue webcast, hosted by HC Andersen Capital
11:00 CET | Virtual
ExpreS2ion is carrying out a rights issue with preferential rights for existing shareholders, through which the company is aiming to raise approximately SEK 60 million. CEO Bent U. Frandsen and CFO Keith Alexander will present the rights issue and take questions. To participate, please register here. For more information about the rights issue, including the prospectus, please click here.
24 June 2024 | 2024 European Society for Animal Cell Technology meeting
14:30 – 16:00 BST | Edinburgh, Scotland
ESACT brings together scientists, engineers and other specialists working with animal cells to promote dialogue and scientific development. ExpreS2ion will be presenting a poster titled Use of Drosophila S2 Cells for Production of Highly Immunogenic Antigens. ExpreS2ion will be part of Poster Session 1 taking place Monday, June 24 from 14:30 to 16:00 BST (15:30 to 17:00 CET). Read more about the conference and register here.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.